{"id":"W4379377976","doi":"10.1080/0284186x.2023.2216339","title":"FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study","year":2023,"lang":"en","type":"article","venue":"Acta Oncologica","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Biotech; Eisai; Mylan; Ipsen; Astellas Pharma Canada; Takeda Pharmaceutical Company; Gilead Sciences; Roche; Novartis; GlaxoSmithKline Australia; Meso Scale Diagnostics; Sanofi; Merck; British Microcirculation Society; Amgen; Pfizer; Bayer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Irinotecan; FOLFIRI; Population; Regimen; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Topotecan; Refractory (planetary science); Surgery; Lung cancer; Retrospective cohort study; Chemotherapy regimen; Oncology; Progressive disease; Cancer; Chemotherapy; Colorectal cancer; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007281885,0.0002693096,0.0005349952,0.0009720293,0.0004449,0.0006019516,0.0002821728,0.000430333,0.001048654],"category_scores_gemma":[0.001279962,0.0002520721,0.0006283278,0.001181928,0.0003153434,0.0003592405,0.0002714686,0.0003019149,0.0002207396],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005860692,"about_ca_system_score_gemma":0.0005751977,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002524232,"about_ca_topic_score_gemma":0.002731827,"domain_scores_codex":[0.9995016,0.00008691466,0.00009291639,0.0001524693,0.00009988782,0.00006620138],"domain_scores_gemma":[0.998817,0.00022035,0.0005638479,0.0001115941,0.0001407792,0.0001464164],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003005764,0.00005710516,0.9950784,0.00006535959,0.0001183928,0.001130755,0.00009984261,0.00003673929,0.0002618186,0.0000225045,0.0001223192,0.00270613],"study_design_scores_gemma":[0.00007498311,0.0009497738,0.9876388,0.00004032502,0.0003541308,0.008232237,0.0003728379,0.0002147424,0.000238672,0.00002864967,0.001842135,0.00001268247],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970289,0.002224916,0.00009520666,0.00002365823,0.000004890167,0.00003248304,0.0002143638,0.000003489127,0.0003721645],"genre_scores_gemma":[0.998759,0.0006683416,0.00006798568,0.00004529004,0.00001896507,0.00001587977,0.0003373863,0.00000184549,0.00008529087],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002524232,"threshold_uncertainty_score":0.005019128,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03943207050000615,"score_gpt":0.385076322317816,"score_spread":0.3456442518178099,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}